These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1059 related items for PubMed ID: 27825112

  • 1. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
    Li M, Chen W, Zhang H, Zhang Y, Ke F, Wu X, Zhang Y, Weng M, Liu Y, Gong W.
    Oncotarget; 2016 Dec 13; 7(50):83060-83070. PubMed ID: 27825112
    [Abstract] [Full Text] [Related]

  • 2. LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.
    Mei J, Liu G, Li R, Xiao P, Yang D, Bai H, Hao Y.
    Biosci Rep; 2021 Dec 22; 41(12):. PubMed ID: 34821362
    [Abstract] [Full Text] [Related]

  • 3. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
    Zhao L, Ren Y, Tang H, Wang W, He Q, Sun J, Zhou X, Wang A.
    Oncotarget; 2015 Dec 29; 6(42):44538-50. PubMed ID: 26517090
    [Abstract] [Full Text] [Related]

  • 4. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY, Jiao DM, Wang J, Hu H, Tang X, Chen J, Mou H, Lu W.
    Oncotarget; 2016 Apr 26; 7(17):24510-26. PubMed ID: 27014910
    [Abstract] [Full Text] [Related]

  • 5. miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1.
    Zhan M, Zhao X, Wang H, Chen W, Xu S, Wang W, Shen H, Huang S, Wang J.
    Tumour Biol; 2016 Aug 26; 37(8):10553-62. PubMed ID: 26852750
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
    Cheng C, Qin Y, Zhi Q, Wang J, Qin C.
    Int J Biol Macromol; 2018 Feb 26; 107(Pt B):2620-2629. PubMed ID: 29080815
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y, Huang S, Guo Y, Li L.
    Biomed Pharmacother; 2018 Oct 26; 106():1357-1363. PubMed ID: 30119207
    [Abstract] [Full Text] [Related]

  • 11. [The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells].
    Wu Y, Guo L, Liu J, Liu R, Liu M, Chen J.
    Zhongguo Fei Ai Za Zhi; 2014 Jan 26; 17(1):1-7. PubMed ID: 24398307
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
    Wang B, Zhang Y, Ye M, Wu J, Ma L, Chen H.
    Curr Drug Metab; 2019 Jan 26; 20(10):804-814. PubMed ID: 31424364
    [Abstract] [Full Text] [Related]

  • 14. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
    Pan J, Li X, Wu W, Xue M, Hou H, Zhai W, Chen W.
    Cancer Lett; 2016 Nov 01; 382(1):64-76. PubMed ID: 27591936
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
    Xu S, Fu GB, Tao Z, OuYang J, Kong F, Jiang BH, Wan X, Chen K.
    Oncotarget; 2015 Sep 22; 6(28):26457-71. PubMed ID: 26238185
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y, Li F, Han D, Wang L, Zhang G, Gao X.
    Oncogene; 2014 Jan 16; 33(3):378-86. PubMed ID: 23318422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.